Literature DB >> 28816351

Recent advances in genomic profiling of adenosquamous carcinoma of the pancreas.

Rebecca Marcus1, Anirban Maitra2, Jason Roszik3,4.   

Abstract

Adenosquamous carcinoma of the pancreas (ASCP) is a mixed tumor type which contains squamous cell carcinoma and also ductal adenocarcinoma components. Due to the rarity of this malignancy, only very limited genomic profiling has been performed. A recent paper by Fang et al. published in The Journal of Pathology contributed to our knowledge of genomic alterations by performing whole-genome and -exome sequencing of 17 ASCP tumors. They found major genomic similarities to pancreatic ductal adenocarcinoma; however, the p53 pathway was altered in a greater proportion of cases, while a high frequency of 3p loss was a distinct copy number alteration pattern observed in ASCP. Laser capture microdissection revealed that adenocarcinoma and squamous carcinoma components of ASCP harbor similar genomic variations, indicating that the origin of tumor components is the same or similar. Although the study published by Fang et al. increases our knowledge of this rare mixed tumor type, further investigation, including RNA sequencing, will be needed to fully characterize this malignancy and to aid the development of novel treatment approaches.
Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  adenosquamous carcinoma of the pancreas; cancer; copy number alterations; next-generation sequencing; somatic mutations

Mesh:

Year:  2017        PMID: 28816351     DOI: 10.1002/path.4959

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  7 in total

1.  Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis.

Authors:  Ayush Sharma; Thomas C Smyrk; Michael J Levy; Mark A Topazian; Suresh T Chari
Journal:  Gastroenterology       Date:  2018-04-30       Impact factor: 22.682

2.  Chemoradiotherapy is associated with improved survival for resected pancreatic adenosquamous carcinoma: a retrospective cohort study from the SEER database.

Authors:  Yuan Fang; Ning Pu; Lei Zhang; Wenchuan Wu; Wenhui Lou
Journal:  Ann Transl Med       Date:  2019-10

3.  ClickGene: an open cloud-based platform for big pan-cancer data genome-wide association study, visualization and exploration.

Authors:  Jia-Hao Bi; Yi-Fan Tong; Zhe-Wei Qiu; Xing-Feng Yang; John Minna; Adi F Gazdar; Kai Song
Journal:  BioData Min       Date:  2019-06-26       Impact factor: 2.522

Review 4.  Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology.

Authors:  Chiara Bazzichetto; Claudio Luchini; Fabiana Conciatori; Vanja Vaccaro; Ilaria Di Cello; Paola Mattiolo; Italia Falcone; Gianluigi Ferretti; Aldo Scarpa; Francesco Cognetti; Michele Milella
Journal:  Int J Mol Sci       Date:  2020-11-22       Impact factor: 5.923

Review 5.  Clinical and Histological Basis of Adenosquamous Carcinoma of the Pancreas: A 30-year Experience.

Authors:  Maitham A Moslim; Max D Lefton; Eric A Ross; Nicholas Mackrides; Sanjay S Reddy
Journal:  J Surg Res       Date:  2020-11-13       Impact factor: 2.192

6.  Cellular organization and histogenesis of adenosquamous carcinoma of the pancreas: evidence supporting the squamous metaplasia concept.

Authors:  Werner Boecker; Katharina Tiemann; Joerg Boecker; Marieta Toma; Michael H Muders; Thomas Löning; Igor Buchwalow; Karl J Oldhafer; Ulf Neumann; Bernd Feyerabend; Andre Fehr; Göran Stenman
Journal:  Histochem Cell Biol       Date:  2020-03-13       Impact factor: 4.304

7.  Development and Validation of Nomograms to Predict Overall Survival and Cancer-Specific Survival in Patients With Pancreatic Adenosquamous Carcinoma.

Authors:  Zhen Yang; Guangjun Shi; Ping Zhang
Journal:  Front Oncol       Date:  2022-03-07       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.